News

The University of Wisconsin-Madison’s Alzheimer’s Disease Research Center and Cerveau Technologies are partnering in research on the stages of Alzheimer’s and other neurodegenerative diseases. Wisconsin established the center in 2009 to focus on preclinical Alzheimer’s. Cerveau is a partnership between Enigma Biomedical Group and Sinotau Pharmaceutical Group. It was created to…

The diabetes drug Symlin (pramlintide) may help scientists develop novel and faster diagnostic tests for Alzheimer’s disease (AD), a study indicates. The research, “An amylin analog used as a challenge test for Alzheimer’s disease,” was published in the journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. At…

Israel’s Neurim Pharmaceuticals is now recruiting up to 500 U.S. patients with mild Alzheimer’s disease for a Phase 2 trial to study the safety and efficacy of its experimental drug, piromelatine. Alzheimer’s is caused by the accumulation of faulty proteins that lead to the formation of beta-amyloid plaques, which greatly…

Roche and MorphoSys will partner on experimental Phase 3 clinical trials to study the effectiveness and safety of gantenerumab in patients with early to mild Alzheimer’s disease. Roche, a Swiss global healthcare company, will start preparing two studies soon, according to MorphoSys, a German biotechnology company that developed gantenerumab. The trials will…

Genentech will start a second Phase 3 clinical trial of crenezumab, an anti-Amyloid-beta antibody for treating Alzheimer’s disease that was developed by its partner, AC Immune. This trial, CREAD2, will complement the current randomized, double-blind, placebo-controlled, parallel group Phase 3 clinical trial (CREAD1, NCT02670083). CREAD1 is evaluating the effectiveness and…

Neurotrope has finished dosing and monitoring patients in a Phase 2 clinical trial to evaluate Bryostatin-1, the company’s lead drug candidate for treatment of moderate to severe Alzheimer’s disease. The randomized, double-blind, placebo-controlled, Phase 2 clinical trial (NCT02431468) is assessing the safety, tolerability and efficacy of bryostatin-1 in 148 people…

The Vanderbilt University Medical Center has passed a key hurdle in its quest to develop a treatment for Alzheimer’s disease with the announcement that the U.S. Food and Drug Administration (FDA) has approved a Phase 1 clinical trial of the therapy. The development marks one of the few times that a university…

Yet another Alzheimer’s disease clinical trial (NCT01741194) has ended in disappointment. Accera, noting that its Phase 3 trial of AC-1204 showed the drug offered no benefits over placebo, blamed its failure on an inadequate uptake of AC-1204 into the bloodstream. “The trial result is disappointing for us and the millions…

Factors known to increase risk for heart disease during middle age – diabetes, high blood pressure and smoking – also raise the risk of dementias such as Alzheimer’s disease later in life. So concludes a study presented at the American Stroke Association’s International Stroke Conference 2017, held Feb. 22-24, in Houston,…

Increased blood sugar levels may lead to Alzheimer’s disease by damaging a protein that is essential in fighting the disease’s early stages, a new study indicates. The report, “Macrophage Migration Inhibitory Factor is subjected to glucose modification and oxidation in Alzheimer’s Disease,” appeared in the journal Scientific Reports. Diabetes is a…